This is a summary of the European public assessment report (EPAR) for Galliprant. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Galliprant.
For practical information about using Galliprant, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Galliprant : EPAR - Summary for the public (PDF/76.55 KB)
First published: 06/02/2018
Last updated: 06/02/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
|Date of issue of marketing authorisation valid throughout the European Union||
13/08/2021 Galliprant - EMEA/V/C/004222 - IB/0015
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
For the treatment of pain associated with mild to moderate osteoarthritis in dogs.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 April 202116/04/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 8-10 December 202011/12/2020